Silo Pharma, Inc. (SILO) is an innovative biopharmaceutical company that focuses on the development of therapeutics for disorders such as fibromyalgia, chronic fatigue, and post-traumatic stress disorder. The company's primary goal is to leverage its proprietary technology to change the lives of people affected by these conditions by offering some of the most revolutionary therapies and treatments available in the market today.
Headquartered in Englewood Cliffs, New Jersey, Silo Pharma is renowned for its commitment to clinical development and the commercialization of novel therapies. The company is supplementing traditional therapeutic drugs with powerful, novel peptide-based drugs to speed up the development and availability of these treatments to patients.
In its bid to better manage neurological and psychiatric disorders, Silo Pharma is extensively engaged in researching and developing novel psilocybin new chemical entities all aimed at dealing with the adverse effects of conditions such as depression, anxiety, and substance abuse disorders. Through collaborations with academic institutions and other pharmaceutical and biotechnology companies, Silo Pharma has been able to make significant strides in developing transformative medicines that promise better patient outcomes.
One crucial aspect of Silo Pharma's operations is its commitment to improving mental health. The company is currently researching the effects of microdosing of psychedelics on mental health, an innovative approach that could potentially revolutionize mental health treatment globally.
As a publicly-traded company (ticker symbol: SILO), Silo Pharma, Inc. underscores its commitment to its shareholders by upholding high standards for financial transparency and accountability. The company's management team comprises of seasoned professionals with a wealth of experience in the pharmaceutical and biotechnology sectors. Their collective expertise is critical in driving the company's mission - to ideally improve patients' lives.
In summary, Silo Pharma, Inc., with its innovative approach and unwavering dedication to bettering human health, positions itself as a major player in the biopharmaceutical industry. The potential global impact of its work cannot be understated, making Silo Pharma an intriguing company to watch as it continues to disrupt the status quo and make impressive strides in drug research and development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Silo Pharma (SILO) has acquired certain software and related intellectual property from Larry King by issuing 150,000 shares of its common stock. The shares are subject to a lock-up period and the agreement includes indemnification clauses for misrepresentations or third-party infringement. This strategic move allows Silo Pharma to fund asset acquisitions using equity while mitigating immediate share liquidity and legal risks.
Silo Pharma (SILO) has acquired intellectual property assets, including software, technology, trademarks, and domain names, from Norsight Consulting Inc. The acquisition was made through an asset purchase agreement, with Silo Pharma issuing Norsight a warrant to purchase up to 300,000 shares of common stock. This strategic move aims to enhance Silo Pharma's operational capabilities and strategic positioning within the pharmaceutical and biotechnology sector.